Specialized Ophthalmology in Seoul · Dedicated International Patient Concierge
MOHW Registered · Foreign Patient Care
en-US
Medical Guide
Choosing a Multifocal IOL Brand: PanOptix and Others
Choosing a multifocal IOL brand: how to read an FDA premarket approval record, what the indications for use really say, and what you can verify yourself.
Schedule a ConsultationSelecting a Multifocal IOL Brand: Comparing PanOptix and Other Premium Lens Options
Medically reviewed by Dr. Cha Deok Sun, Board-certified ophthalmologist (Korean Ophthalmological Society)
Choosing a multifocal IOL brand is a different task from choosing a lens category, and most patients are given help with the second and left alone with the first. Once you and your surgeon have settled on an implant that provides more than one working distance, a brand name appears — and almost everything written about it in public is written by someone selling it. This article is about the part of the decision you can actually do yourself: finding the regulatory record behind a named lens, reading it, and knowing which questions the record answers and which it cannot.
No prices appear here, and no claim is made that one brand outperforms another. What follows is a method, demonstrated on a lens whose record is public, and a short list of the questions that no brand name will ever settle for your particular eye.
A brand is a specific device with a specific file
The useful mental shift is to stop treating a lens name as a product and start treating it as a regulatory entity. In the United States an implanted intraocular lens of this type is a Class III device, and Class III devices reach the market through premarket approval — the FDA's process of scientific and regulatory review to evaluate the safety and effectiveness of devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury.
That means a named lens has a file. The file has a number, a decision date, an applicant, an approval order with its own wording, a summary of safety and effectiveness, and labeling. The FDA publishes consumer guidance on how to find out whether a given device has been cleared or approved for marketing, and the databases it points to are open to anyone.
This is the single most valuable thing a patient can know when comparing brands: you are not restricted to the manufacturer's description.
Where the record lives, and how to read one
The premarket approval database is searchable by applicant, device, product code, decision date or approval number. A record returns a consistent set of fields, and each field tells you something different.
- Device gives the exact approved name, which is often longer and more specific than the marketing name.
- Generic name tells you what the FDA considers the device to be. For this category it reads "Lens, multifocal intraocular."
- Regulation number and product code are how you confirm you are comparing like with like. Multifocal intraocular lenses sit under regulation 886.3600 with product code MFK.
- Applicant names the company legally responsible.
- Decision date tells you when that particular authorization was granted — not when the brand first existed.
- Advisory committee indicates the FDA panel area; for these lenses it is Ophthalmic.
- Approval order statement contains the indications for use in the agency's own words. This is the field to read first.
- Approval order, summary of safety and effectiveness and labeling are published documents attached to the record.
- Clinical trials sometimes links the registered study behind the approval.
Learn those nine fields and you can read any lens brand's record in about five minutes.
A worked example: the record behind PanOptix
Take a lens whose record is straightforward to find. The AcrySof IQ PanOptix Trifocal Intraocular Lens and AcrySof IQ PanOptix Toric Trifocal Intraocular Lens appear in the FDA's premarket approval database under PMA number P040020, supplement S087, with Alcon Research, Ltd. as applicant. The supplement type is recorded as panel track, the supplement reason as a change to design, components, specifications or material, the application was received on January 31, 2019 and the decision date is August 26, 2019. The generic name is "Lens, multifocal intraocular," the regulation number is 886.3600 and the product code is MFK. The record links the registered clinical trial NCT01424189 and publishes the approval order, the summary of safety and effectiveness data, and two parts of labeling.
The approval order statement is where the substance is. It states that the AcrySof IQ PanOptix Trifocal Intraocular lens is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed, and that the lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared with a monofocal intraocular lens.
The toric version carries its own wording in the same order: indicated for primary implantation in the capsular bag in the posterior chamber for the visual correction of aphakia and the reduction of residual refractive astigmatism, in adult patients in whom a cataractous lens has been removed, with the same statement about mitigating presbyopia.
Read those two paragraphs next to each other and you have learned something a brochure would not have told you plainly: within one brand, there are two differently indicated devices, and which one applies to you depends on a corneal measurement rather than a preference.
Why a brand's record is a stack, not a single document
One detail trips up almost every first-time reader. The number P040020 does not belong to PanOptix. It belongs to a product line.
The original P040020 record is for the AcrySof ReSTOR apodized diffractive optic posterior chamber intraocular lenses, models MA60D3 and SA60D3, with a decision date of March 21, 2005. Its approval order states that the device is indicated for the visual correction of aphakia secondary to removal of a cataractous lens in adult patients with and without presbyopia who desire near, intermediate and distance vision with increased spectacle independence, with the lens intended to be placed in the capsular bag.
Everything after that is a supplement, and there are more than a hundred of them. The FDA attaches an explicit warning to supplement records: a supplement may have changed the device description, function or indication from that approved in the original application, and the reader should look at the original record for more information. It attaches the mirror-image warning to original records: the device has supplements, the description or indication may have changed, and the labeling shown is the version at the time of approval of the original application or of a panel track supplement and may not represent the most recent labeling.
The practical lesson for brand comparison is to check the supplement number and the decision date, not only the approval number. Two lenses can share a premarket approval number, be separated by fourteen years of development, and carry materially different indications.
The clinical evidence behind a lens, and how to find it
The summary of safety and effectiveness data attached to a record is the document that describes what was studied and what was found. It is technical, but parts of it are readable, and it is the only account of a brand's trial that is not written by the marketing department.
For the PanOptix approval, the FDA has also published a short account of how patient-reported outcomes were used in the review — the kind of document that is unusually useful to a patient. It describes the AcrySof IQ PanOptix Trifocal IOL, model TFNT00, as a Class III ultraviolet absorbing and blue light filtering foldable multifocal intraocular lens implanted after cataract removal, and it explains that two patient-reported outcome instruments were used to assess endpoints in the pivotal clinical investigation: the Questionnaire for Visual Disturbances, abbreviated QUVID, and the IOL satisfaction questionnaire, abbreviated IOLSAT. Both were developed by the device sponsor, and the FDA's device center made the final determination that they were fit for purpose during the review.
The endpoints are worth knowing because they are stated in human terms. The FDA records that the secondary safety endpoint was an estimate of the rates of "severe" and "most bothersome" visual disturbances as reported by patients on the QUVID instrument, which was also used to assess rates of all visual disturbances rather than only those two categories. One of two secondary effectiveness endpoints was the proportion of participants who answered "never" to the first question of the satisfaction questionnaire: overall, in the past seven days, how often did you need to wear eyeglasses to see? The FDA notes that this endpoint directly informed the indications for use and the labeling, including the statement that the lens maintains comparable distance visual acuity with a reduced need for eyeglasses compared with a monofocal lens.
That is a rare and instructive thing to see: a sentence in a lens's official indication traced back to a questionnaire answered by trial participants. When you compare brands, this is the level at which a real comparison happens — what was measured, in whom, and how the result was phrased.
What to do when a brand's record cannot be found
Sometimes a lens you are offered has no record you can locate. There are legitimate reasons for that, and the most common one is geography.
Device authorization is national. A lens approved in one country is approved by that country's authority under that country's law; a lens marketed in Korea, Japan or anywhere else may be entirely properly authorized there without appearing in a United States database. The absence of an American record is therefore not evidence against a lens. But it does mean the verification route described in this article is unavailable to you, and the honest response is to ask the clinic directly which national authority authorized the specific lens and under what identifier, rather than to assume.
What you should not do is substitute marketing material for a regulatory record. Promotional copy is written to persuade; an approval order is written to constrain. Where the two differ, the second is the one that binds.
The questions a brand name cannot answer
Here is the uncomfortable part of brand comparison: the record describes the device, and your result depends on the device and your eye together.
The National Eye Institute puts the measurement step plainly. About a week before cataract surgery, it says, your eye doctor will carry out tests to measure the size and shape of your eye, and those tests are what help the doctor choose the right kind of artificial lens. No brand record substitutes for that, and no brand is a good choice in an eye whose measurements do not suit it.
The identity of the implanted lens does matter afterwards, though, and in a specific way. EyeWiki, the American Academy of Ophthalmology's clinical reference, notes that when a patient reports unwanted optical images after cataract surgery, knowledge of the specific manufacturer and lens type is important to the assessment. It relates positive dysphotopsia — bright artifacts described as arcs, streaks, starbursts, rings or halos — to the material, design and location of the implant, and lists lens material, edge design, index of refraction and surface reflectivity among the risk factors. It also reports that most such experiences resolve or are neuroadapted to.
So the brand is worth recording for your own files, not because it predicts your outcome, but because if something needs explaining later, the first question will be which lens is in your eye.
Questions to take into the consultation
- Which lens, by exact device name and model, are you recommending for me, and why that one rather than another in the same category?
- What is my measured corneal astigmatism, and does it place me inside or outside the indication for the non-toric version?
- Which national authority authorized this lens, and under what approval identifier?
- What does the approved indication say about the distances this lens is designed to deliver?
- What findings in my examination would make you change the recommendation?
- Will the exact lens and model implanted be written in the records I take home?
Every one of those has a factual answer. None of them requires you to take a brand claim on trust.
Where Jamsil Samsung Eye Clinic fits
Jamsil Samsung Eye Clinic operates cataract and presbyopia surgery as one of its two main specialty lines from its premises on Olympic-ro in Songpa-gu, Seoul. For presbyopia surgery, the clinic's listed lens is a Clareon PanOptix Pro trifocal intraocular lens, implanted in place of the natural lens and intended to provide vision at multiple distances rather than at distance alone. Its stated candidates are adults with presbyopia, cataracts, or both who are found suitable for intraocular lens surgery after an eye examination, and its stated determinants of suitability are overall eye health, the condition of the cornea and retina, ocular history and individual visual needs.
The clinic's cataract pathway begins with a precision examination and lens selection, and it describes a presbyopia precision exam program that measures refractive power, maps corneal topography and examines the anterior segment and fundus before any treatment strategy is chosen. Dr. Cha Deok Sun, one of the clinic's four board-certified ophthalmologists, trained in cornea and cataract surgery at Seoul National University Hospital, holds a 2018 patent for an intraocular lens used in cataract surgery, and is a member of the Korean Society of Cataract and Refractive Surgery as well as ASCRS and ESCRS.
Background on the practice and the way its service lines are organized is set out on the about us page. If you want the measurement-led answer rather than a brand-led one, that conversation starts at the consultation and appointment page, where correspondence is handled in English and a written quotation covering any fee is issued once the plan is settled. Confirm amounts with the clinic directly.
The Bottom Line
- A lens brand is a regulated device with a public file: in the United States these lenses are Class III devices authorized through premarket approval, with a published approval order, summary of safety and effectiveness, and labeling.
- Confirm you are comparing like with like using the generic name "Lens, multifocal intraocular," regulation number 886.3600 and product code MFK.
- Read the approval order statement first — the FDA record for P040020/S087, decided August 26, 2019, indicates the AcrySof IQ PanOptix Trifocal lens for patients with less than 1 diopter of pre-existing corneal astigmatism, while the toric version is separately indicated for reduction of residual refractive astigmatism.
- A premarket approval number covers a product line, not one lens: the original P040020 record, decided March 21, 2005, is for the AcrySof ReSTOR apodized diffractive lens, and the FDA warns that supplements may change the description or indication.
- Patient-reported outcomes are the part of the evidence a patient can relate to: the FDA describes the QUVID and IOLSAT instruments used in the PanOptix pivotal investigation and the eyeglasses-use question that informed the approved labeling.
Frequently Asked Questions
How do I find the FDA record for a particular lens?
Through the FDA's premarket approval database, which is searchable by applicant, device name, product code, decision date or approval number. Each record returns the approved device name, the generic name, the regulation number and product code, the applicant, the decision date, the approval order statement, and links to the published approval order, summary of safety and effectiveness and labeling.
What does the PanOptix approval actually say?
The FDA record for P040020, supplement S087, with a decision date of August 26, 2019, indicates the AcrySof IQ PanOptix Trifocal Intraocular lens for primary implantation in the capsular bag for the visual correction of aphakia in adults with less than 1 diopter of pre-existing corneal astigmatism, stating that it mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity with reduced need for eyeglasses compared with a monofocal lens.
Why does one approval number cover several different lenses?
Because supplements accumulate under the original number. The FDA notes on a supplement record that the supplement may have changed the device description, function or indication from the original approval, and on an original record that supplements exist and the labeling shown may not be the most recent. Always check the supplement number and decision date alongside the approval number.
What were QUVID and IOLSAT?
The FDA describes them as the two patient-reported outcome instruments used to assess endpoints in the pivotal clinical investigation for the AcrySof IQ PanOptix Trifocal IOL — a questionnaire for visual disturbances and an intraocular lens satisfaction questionnaire. Both were developed by the device sponsor, with the FDA's device center making the final fit-for-purpose determination during the review.
Does it matter which brand goes into my eye?
It matters less than the measurements, and it matters afterwards. EyeWiki notes that when a patient reports unwanted optical images following cataract surgery, knowledge of the specific manufacturer and lens type is important to the assessment, and relates positive dysphotopsia to the implant's material, design and location. Ask for the exact lens and model to be recorded in your notes.
What if the lens I am offered has no United States record?
Device authorization is national, so a lens may be properly authorized by another country's regulator without appearing in a United States database. The absence of an American record is not evidence against a lens, but the verification route described here will not be available. Ask the clinic which authority authorized the lens and under what identifier.
Who decides which lens design suits my eye?
The examination does. The National Eye Institute states that about a week before cataract surgery the eye doctor performs tests that measure the size and shape of the eye, and that those tests help the doctor choose the right kind of artificial lens. Candidacy for a given lens follows from those measurements and from the health of the cornea, retina and ocular surface.
This article is for general informational purposes and does not constitute individualized medical advice. It is not a self-diagnosis tool. Surgical candidacy, technique, and expected outcomes can only be determined through a consultation with a qualified ophthalmologist.
More Articles
Continue reading our clinical ophthalmology guides.
LASIK Cost Korea vs US: How Each System Sets Prices
LASIK cost in Korea vs the US differs because each system treats vision correction as elective. How pricing is structured, and how to request a real quote.
Learn More
Dr. Kim Byoung Jin: Ophthalmologist in Seoul, Korea
Dr. Kim Byoung Jin is a board-certified ophthalmologist and representative director at Jamsil Samsung Eye Clinic, Seoul. His training and focus, explained.
Learn More
Book an Online Consultation: Korea Eye Clinic Guide
Book an online consultation with a Korea eye clinic: the channels this Seoul practice documents, the time-zone arithmetic, and what to assemble up front.
Learn More